Hua Gao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1571025/publications.pdf

Version: 2024-02-01

516215 676716 44 620 16 22 citations h-index g-index papers 752 47 47 47 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Functions and Mechanisms of Tumor Necrosis Factor-α and Noncoding RNAs in Bone-Invasive Pituitary Adenomas. Clinical Cancer Research, 2018, 24, 5757-5766.	3.2	43
2	The role of FSCN1 in migration and invasion of pituitary adenomas. Molecular and Cellular Endocrinology, 2016, 419, 217-224.	1.6	40
3	Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas. BMC Cancer, 2015, 15, 272.	1.1	34
4	EGFL7 participates in regulating biological behavior of growth hormone–secreting pituitary adenomas via Notch2/DLL3 signaling pathway. Tumor Biology, 2017, 39, 101042831770620.	0.8	32
5	DAPT, a Î ³ -Secretase Inhibitor, Suppresses Tumorigenesis, and Progression of Growth Hormone-Producing Adenomas by Targeting Notch Signaling. Frontiers in Oncology, 2019, 9, 809.	1.3	31
6	Long non-coding RNA C5orf66-AS1 is downregulated in pituitary null cell adenomas and is associated with their invasiveness. Oncology Reports, 2017, 38, 1140-1148.	1.2	30
7	ldentification of Serum miRNA-423-5p Expression Signature in Somatotroph Adenomas. International Journal of Endocrinology, 2019, 2019, 1-12.	0.6	30
8	Obesity regulates miRâ€467/HoxA10 axis on osteogenic differentiation and fracture healing by BMSCâ€derived exosome LncRNA H19. Journal of Cellular and Molecular Medicine, 2021, 25, 1712-1724.	1.6	28
9	Plate Fixation Versus Intramedullary Nailing for Bothâ€Bone Forearm Fractures: A Metaâ€analysis of Randomized Controlled Trials and Cohort Studies. World Journal of Surgery, 2017, 41, 722-733.	0.8	27
10	Whole-exome sequencing identifies variants in invasive pituitary adenomas. Oncology Letters, 2016, 12, 2319-2328.	0.8	26
11	ESR1 and its antagonist fulvestrant in pituitary adenomas. Molecular and Cellular Endocrinology, 2017, 443, 32-41.	1.6	23
12	Evaluation of Singh Index and Osteoporosis Self-Assessment Tool for Asians as risk assessment tools of hip fracture in patients with type 2 diabetes mellitus. Journal of Orthopaedic Surgery and Research, 2017, 12, 37.	0.9	20
13	Analysis of clinical factors and PDGFR- \hat{l}^2 in predicting prognosis of patients with clival chordoma. Journal of Neurosurgery, 2018, 129, 1429-1437.	0.9	19
14	Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas. Journal of Neuro-Oncology, 2017, 132, 199-206.	1.4	18
15	Aberrant expression of the sFRP and WIF1 genes in invasive non-functioning pituitary adenomas. Molecular and Cellular Endocrinology, 2018, 474, 168-175.	1.6	18
16	Clinical Features and Prognostic Factors of Children and Adolescents with Clival Chordomas. World Neurosurgery, 2017, 98, 323-328.	0.7	17
17	Role of EGFL7/EGFR-signaling pathway in migration and invasion of growth hormone-producing pituitary adenomas. Science China Life Sciences, 2018, 61, 893-901.	2.3	16
18	Clinical and functional comparison of endoprosthetic replacement with intramedullary nailing for treating proximal femur metastasis. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 209-214.	0.7	16

#	Article	IF	Citations
19	SNF5 as a prognostic factor in skull base chordoma. Journal of Neuro-Oncology, 2018, 137, 139-146.	1.4	14
20	Maffucci syndrome with unilateral limb: a case report and review of the literature. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2013, 25, 254-8.	0.7	12
21	The Apoptosis Regulator 14-3-3î· and Its Potential as a Therapeutic Target in Pituitary Oncocytoma. Frontiers in Endocrinology, 2019, 10, 797.	1.5	10
22	A two‑circRNA signature predicts tumour recurrence in clinical non‑functioning pituitary adenoma. Oncology Reports, 2018, 41, 113-124.	1.2	9
23	Metabolic profiling reveals distinct metabolic alterations in different subtypes of pituitary adenomas and confers therapeutic targets. Journal of Translational Medicine, 2019, 17, 291.	1.8	9
24	JAG1, Regulated by microRNA-424-3p, Involved in Tumorigenesis and Epithelial–Mesenchymal Transition of High Proliferative Potential-Pituitary Adenomas. Frontiers in Oncology, 2020, 10, 567021.	1.3	9
25	Impact of SLC20A1 on the Wnt∫i²â€′catenin signaling pathway in somatotroph adenomas. Molecular Medicine Reports, 2019, 20, 3276-3284.	1.1	8
26	High-Dose Neural Stem/Progenitor Cell Transplantation Increases Engraftment and Neuronal Distribution and Promotes Functional Recovery in Rats after Acutely Severe Spinal Cord Injury. Stem Cells International, 2019, 2019, 1-17.	1.2	8
27	The Effects of Smad3 on Adrenocorticotropic Hormone–Secreting Pituitary Adenoma Development, Cell Proliferation, Apoptosis, and Hormone Secretion. World Neurosurgery, 2018, 114, e329-e337.	0.7	7
28	Neuro-endoscope for skull base tumors. Clinical Neurology and Neurosurgery, 2018, 170, 102-105.	0.6	7
29	Expression of Cyclin E/Cdk2/p27Kip1 in Growth Hormone Adenomas. World Neurosurgery, 2019, 121, e45-e53.	0.7	7
30	Genomic and transcriptomic analysis of pituitary adenomas reveals the impacts of copy number variations on gene expression and clinical prognosis among prolactin-secreting subtype. Aging, 2021, 13, 1276-1293.	1.4	7
31	Attenuation of EGFL7 Expression Inhibits Growth Hormone–Producing Pituitary Adenomas Growth and Invasion. Human Gene Therapy, 2018, 29, 1396-1406.	1.4	6
32	A New Accurate, Simple and Less Radiation Exposure Device for Distal Locking of Femoral Intramedullary Nails. International Journal of General Medicine, 2021, Volume 14, 4145-4153.	0.8	5
33	CDKN2A (p16INK4A) affects the anti‑tumor effect of CDK inhibitor in somatotroph adenomas. International Journal of Molecular Medicine, 2020, 47, 500-510.	1.8	5
34	Prognostic Value of a Category Based on Electron Microscopic Features of Clival Chordomas. World Neurosurgery, 2017, 99, 282-287.	0.7	4
35	P21Waf1/Cip1 and p27Kip1 are correlated with the development and invasion of prolactinoma. Journal of Neuro-Oncology, 2018, 136, 485-494.	1.4	4
36	Association of TGF-Î ² 1 and WIF1 Expression with 36 Paired Primary/Recurrent Nonfunctioning Pituitary Adenomas: A High-Throughput Tissue Microarrays Immunohistochemical Study. World Neurosurgery, 2018, 119, e23-e31.	0.7	4

#	Article	IF	CITATIONS
37	Assessment of sFRP4 as a bio-marker for predicting aggressiveness and recurrence of growth hormone-secreting pituitary adenomas. Oncology Reports, 2016, 35, 2991-2999.	1.2	3
38	Differential expression of the Notch1 receptor, and its ligands Dll1, Dll3 and Dll4 in distinct human pituitary adenoma subtypes. Oncology Letters, 2017, 13, 4533-4539.	0.8	3
39	Epithelial–Mesenchymal Transition Induced by SMAD4 Activation in Invasive Growth Hormone-Secreting Adenomas. Open Chemistry, 2018, 16, 571-582.	1.0	3
40	Use of micro-positron emission tomography with 18F-fallypride to measure the levels of dopamine receptor-D2 and 18F-FDG as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 rats. OncoTargets and Therapy, 2016, 9, 2057.	1.0	2
41	Functional characterization of DLK1/MEG3 locus on chromosome 14q32.2 reveals the differentiation of pituitary neuroendocrine tumors. Aging, 2021, 13, 1422-1439.	1.4	2
42	Anti-EGFL7 antibodies inhibit rat prolactinoma MMQ cells proliferation and PRL secretion. Open Chemistry, 2018, 16, 621-626.	1.0	1
43	Clinical and functional comparison of dynamic hip screws and intramedullary nails for treating proximal femur metastases in older individuals. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 395-402.	0.7	1
44	Anti-c-myc efficacy block EGFL7 induced prolactinoma tumorigenesis. Open Chemistry, 2019, 17, 1501-1508.	1.0	0